Caribou Biosciences, Inc. (CRBU)
0.4602
-0.02
(-4.36%)
USD |
NASDAQ |
Oct 09, 16:00
0.47
+0.01
(+2.13%)
After-Hours: 05:48
Caribou Biosciences Gross Profit Margin (Quarterly) : 58.31% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 58.31% |
| March 31, 2026 | 72.92% |
| December 31, 2025 | 82.69% |
| September 30, 2025 | 71.29% |
| June 30, 2025 | 56.24% |
| March 31, 2025 | 50.49% |
| December 31, 2024 | 42.99% |
| September 30, 2024 | 41.85% |
| June 30, 2024 | 75.29% |
| March 31, 2024 | 70.77% |
| December 31, 2023 | 44.52% |
| September 30, 2023 | 91.10% |
| June 30, 2023 | 70.01% |
| Date | Value |
|---|---|
| March 31, 2023 | 68.48% |
| December 31, 2022 | 75.54% |
| September 30, 2022 | 67.54% |
| June 30, 2022 | 79.53% |
| March 31, 2022 | 69.67% |
| December 31, 2021 | 89.33% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 72.58% |
| Vir Biotechnology, Inc. | 98.83% |
| Arrowhead Pharmaceuticals, Inc. | 91.15% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | 39.18% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -82.03% |
| Return on Assets | -58.27% |
| Return on Invested Capital | -67.81% |
| Profit Margin (Quarterly) | -1.62K% |
| Operating Margin (Quarterly) | -1.69K% |
| Return on Net Operating Assets | -402.7% |